Glucagon

Overview

Glucagon is a 29-amino acid peptide hormone produced by the alpha cells of the pancreatic islets of Langerhans. It serves as the principal counter-regulatory hormone to Insulin, maintaining blood glucose homeostasis by stimulating hepatic glucose output when circulating glucose levels fall. The dynamic interplay between insulin (which lowers glucose) and glucagon (which raises glucose) represents a fundamental endocrine feedback loop essential for metabolic survival.

Glucagon was discovered in 1923 by Charles Kimball and John Murlin at the University of Rochester, who identified a hyperglycemic factor in pancreatic extracts that contaminated early insulin preparations. The name derives from "glucose agonist." Its amino acid sequence was determined by Wally Bromer and colleagues in 1957, and the peptide was among the earliest to be fully characterized at the molecular level.

Clinically, glucagon has been used for decades as an emergency treatment for severe hypoglycemia, particularly in patients with diabetes who are unable to take oral glucose. Recent formulations have improved accessibility:

• Glucagon Emergency Kit — traditional lyophilized powder requiring reconstitution before injection
• Baqsimi — intranasal glucagon powder (approved 2019), eliminating the need for injection
• Gvoke — ready-to-use liquid glucagon autoinjector (approved 2019)
• Dasiglucagon (Zegalogue) — a glucagon analog with improved stability in liquid formulation

Beyond emergency hypoglycemia, glucagon's biology has gained renewed therapeutic interest through the development of glucagon receptor agonists for obesity (exploiting glucagon's effects on energy expenditure and lipid metabolism) and dual/triple agonists such as Survodutide (GLP-1/glucagon) and Retatrutide (GLP-1/GIP/glucagon) that deliberately incorporate glucagon receptor activity alongside incretin signaling.

Structure and Sequence

Glucagon is a linear 29-amino-acid peptide with no disulfide bonds:

Sequence: His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr

• Molecular weight: 3,482.8 g/mol
• Key structural features:
  • N-terminal homology with GLP-1: The first 12 residues share significant homology with glucagon-like peptide-1, reflecting their derivation from the same proglucagon precursor
  • Alpha-helical structure: Residues 10-29 adopt an amphipathic alpha-helix in solution and upon receptor binding
  • Instability in solution: Glucagon rapidly aggregates and forms fibrils in aqueous solution at physiological pH, which historically necessitated lyophilized formulations requiring reconstitution immediately before use
  • N-terminal His1: Critical for receptor activation; the imidazole side chain interacts with the transmembrane domain of the glucagon receptor

Proglucagon processing: The proglucagon gene encodes a 160-amino-acid proglucagon precursor that is differentially processed:

• In pancreatic alpha cells: Prohormone convertase 2 (PC2) liberates glucagon, glicentin-related pancreatic polypeptide (GRPP), and the major proglucagon fragment (MPGF)
• In intestinal L-cells: Prohormone convertase 1/3 (PC1/3) liberates GLP-1, GLP-2, oxyntomodulin, and glicentin (glucagon remains embedded within larger fragments)

This tissue-specific processing means the same gene produces the glucose-raising hormone glucagon in the pancreas and the glucose-lowering hormone GLP-1 in the gut.

Mechanism of Action

Glucagon Receptor Signaling

The glucagon receptor (GCGR) is a class B G-protein coupled receptor expressed predominantly in the liver, with lower expression in kidney, heart, adipose tissue, and brain:

Primary hepatic signaling:

• Gs-coupled activation of adenylate cyclase increases cAMP
• Protein kinase A (PKA) phosphorylates key metabolic enzymes:
  • Glycogen phosphorylase — activated, promoting glycogen breakdown (glycogenolysis)
  • Glycogen synthase — inhibited, preventing glycogen synthesis
  • Phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase — gene expression upregulated, promoting gluconeogenesis
• CREB (cAMP response element-binding protein) activation drives transcriptional changes in gluconeogenic gene expression

Metabolic Effects

Hepatic glucose output (primary):

• Glycogenolysis: rapid mobilization of hepatic glycogen stores (minutes)
• Gluconeogenesis: conversion of amino acids, lactate, and glycerol to glucose (hours)
• These two processes account for the acute and sustained hyperglycemic response to glucagon

Lipid metabolism:

• Stimulation of hepatic fatty acid oxidation
• Promotion of ketogenesis from fatty acid substrates
• Reduction of hepatic lipid content (relevant to NASH/MAFLD therapeutic interest)
• Activation of brown adipose tissue thermogenesis

Energy expenditure:

• Glucagon increases resting energy expenditure through hepatic substrate cycling and enhanced thermogenesis
• This effect has generated interest in glucagon receptor agonism as a component of obesity pharmacotherapy

Amino acid metabolism:

• Promotes hepatic amino acid uptake and ureagenesis
• The "liver-alpha cell axis" describes the feedback loop where amino acids stimulate glucagon secretion, and glucagon enhances hepatic amino acid catabolism

Counter-Regulatory Response

Glucagon is the first-line defense against hypoglycemia:

1. Falling blood glucose is sensed by alpha cells and central glucose sensors
2. Glucagon secretion increases while insulin secretion decreases
3. Hepatic glycogenolysis rapidly restores blood glucose
4. In diabetes, this counter-regulatory response is often impaired, increasing hypoglycemia risk

Research Summary

Area	Study / Context	Key Finding	Reference
Hypoglycemia rescue	Standard of care	IM/SC glucagon (1 mg) reliably reverses severe hypoglycemia within 10-15 minutes	Clinical standard since 1960s
Nasal glucagon	Phase 3 trials	Baqsimi (3 mg intranasal) non-inferior to IM glucagon for hypoglycemia rescue; 98.7% success rate	Rickels et al., 2016; FDA approval 2019
Dual agonism (GLP-1/glucagon)	Survodutide Phase 2	Dual GLP-1/glucagon agonist produced up to 14.9% body weight loss at 46 weeks in obesity	Lancet, 2024
Triple agonism	Retatrutide Phase 2	GLP-1/GIP/glucagon triple agonist produced up to 24.2% weight loss at 48 weeks	Jastreboff et al., 2023 (NEJM)
NASH/MAFLD	Preclinical and early clinical	Glucagon receptor agonism reduces hepatic steatosis through enhanced fatty acid oxidation	Pocai et al., 2009; multiple Phase 2 trials
Glucagon receptor antagonism	Diabetes trials	GCGR antagonists reduce HbA1c but cause alpha-cell hyperplasia and LDL elevation	Kazda et al., 2016

Pharmacokinetics

• Plasma half-life: 3-6 minutes; rapidly degraded by dipeptidyl peptidase-4 (DPP-4) and neprilysin
• Normal fasting plasma levels: 50-100 pg/mL
• Emergency dosing (IM/SC): 1 mg for adults; blood glucose typically rises within 10-15 minutes
• Nasal dosing (Baqsimi): 3 mg single-use device; peak plasma at approximately 15 minutes
• Onset of action: 8-10 minutes (IM); similar for nasal; glucose peak at 20-30 minutes
• Duration: approximately 60-90 minutes; glycogen stores must be present for glycogenolytic response
• Hepatic first-pass: glucagon reaching the liver via portal blood is substantially extracted in first pass (40-80%); exogenous routes bypass portal delivery
• Stability limitation: native glucagon forms amyloid fibrils in solution, requiring lyophilized storage; dasiglucagon contains amino acid substitutions that confer solution stability

Common Discussion Topics

Glucagon in Modern Obesity Pharmacology

The incorporation of glucagon receptor agonism into multi-receptor obesity drugs represents a paradigm shift. While isolated glucagon administration raises blood glucose (counterproductive in metabolic disease), combining glucagon signaling with GLP-1 agonism produces a complementary metabolic profile: GLP-1 provides glucose lowering and appetite suppression while glucagon contributes enhanced energy expenditure, lipid oxidation, and hepatic fat reduction. The clinical results of Retatrutide (triple agonist) and Survodutide (dual agonist) suggest that calibrated glucagon inclusion may enhance weight loss beyond what GLP-1 agonism alone achieves.

Hypoglycemia Rescue Innovation

For decades, glucagon emergency treatment required a cumbersome multi-step reconstitution process (mixing lyophilized powder with diluent in a syringe) during a high-stress emergency. The approval of nasal (Baqsimi) and ready-to-use autoinjector (Gvoke) formulations addressed a major usability gap, enabling bystanders and caregivers to administer glucagon without injection technique or reconstitution. These advances are particularly important for pediatric patients and for caregivers managing type 1 diabetes.

The Liver-Alpha Cell Axis

Recent research has elucidated a feedback loop between hepatic amino acid metabolism and pancreatic alpha cell glucagon secretion. Elevated circulating amino acids (particularly alanine, glutamine, and arginine) stimulate alpha cell glucagon release, and glucagon in turn promotes hepatic amino acid catabolism. Disruption of this axis (as occurs with glucagon receptor antagonism or liver disease) leads to hyperaminoacidemia and alpha cell hyperplasia, a finding that complicated glucagon receptor antagonist drug development.

Impaired Counter-Regulation in Diabetes

In type 1 diabetes and advanced type 2 diabetes, the glucagon counter-regulatory response to hypoglycemia becomes progressively impaired. Alpha cells lose their ability to appropriately increase glucagon secretion when glucose falls, contributing to hypoglycemia unawareness — a dangerous condition in which patients fail to perceive low blood sugar. Understanding and restoring the counter-regulatory glucagon response remains an important goal in diabetes management.

Dosing Protocols

The following dosing information reflects FDA-approved clinical guidelines for glucagon emergency use. Always consult a qualified healthcare professional.

Indication	Formulation	Dose	Route
Severe hypoglycemia (adults/children >25 kg)	Glucagon Emergency Kit	1 mg	IM or SC (reconstitute immediately before use)
Severe hypoglycemia (children <25 kg)	Glucagon Emergency Kit	0.5 mg	IM or SC
Severe hypoglycemia (adults/children >4 yrs)	Baqsimi (nasal)	3 mg (one actuation)	Intranasal
Severe hypoglycemia (adults)	Gvoke (autoinjector)	1 mg	SC
Severe hypoglycemia (children 2-11 yrs)	Gvoke (autoinjector)	0.5 mg	SC
GI diagnostic procedures	Glucagon injection	0.2-2 mg (varies by procedure)	IM or IV

Administration notes: For hypoglycemia rescue, place the patient on their side to prevent aspiration if vomiting occurs. Response (blood glucose rise) is typically seen within 10-15 minutes. Give oral carbohydrates as soon as the patient is able to swallow. A second dose may be given if no response within 15 minutes. Glucagon is ineffective if hepatic glycogen stores are depleted (prolonged fasting, starvation, adrenal insufficiency).

Related Compounds

• Insulin — The primary glucose-lowering hormone, whose actions glucagon directly opposes in hepatic glucose metabolism
• Semaglutide — A GLP-1 agonist (derived from the same proglucagon precursor) now combined with glucagon signaling in next-generation obesity therapies
• Retatrutide — A triple GLP-1/GIP/glucagon agonist incorporating glucagon receptor activity for enhanced weight loss and metabolic effects
• Survodutide — A dual GLP-1/glucagon agonist leveraging glucagon's energy expenditure and hepatic effects
• Exenatide — The first-in-class GLP-1 agonist, representing the incretin side of proglucagon biology